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Introduction
Human chorionic gonadotropin (hCG) is employed as a reliable 
index of pregnancy and is the basis of most diagnosis kits in the market. 
It is not normally secreted in blood (or urine) by any healthy non 
pregnant female or male. Bob (Robert) Edwards , who got the Nobel 
prize for this work reported its presence in the culture fluid of eggs 
fertilized in vitro [1], thus pointing to its synthesis by the early embryo 
prior to its transfer to the uterus. It has a crucial role in implantation of 
the embryo onto the uterus. Marmoset embryos exposed to anti-hCG 
antibodies fail to implant, whereas the same embryos exposed to normal 
globulins implant perfectly [2]. Besides implantation and establishment 
of pregnancy, hCG has a central role in maintenance of pregnancy. It 
is responsible for production of progesterone by the corpus luteum of 
the female up to about 7 weeks of pregnancy before the placental cells 
assume this function. Immunization against hCG causes abortion of 
the fetus up to 6-7 weeks of pregnancy. The above mentioned two well 
proven outcomes of immunization against hCG provide evidence for 
the critical role of hCG in establishment and sustenance of pregnancy. 
An immunogenic vaccine against hCG would and should prevent 
pregnancy to occur. Is it indeed the case? Have there been appropriate 
developments to support this thesis? Is a Birth Control Vaccine feasible 
based on anti-hCG approach, which is safe and reversible? Would this 
vaccine be free from derangement of menstrual regularity and bleeding 
profiles, which are frequent problems of many contraceptives? This 
article will review these issues. In addition; it will cite publications 
reporting the unexpected expression of hCG in advanced stage cancers, 
that are invariably refractory to currently available chemotherapeutic 
drugs and have poor prognosis. Can immunotherapy with the anti- 
hCG vaccine and anti-hCG antibodies prolong their lifespan? Last 
but not of less interest is the reported obesity & insulin resistance in 
transgenic hCG β mice created by Prof Iipo Hutaniemi at Imperial 
College London & Dr. Susana Rulli at Instituto de Biologia y Medicina 
Experimental CONICET Buenos Aires Argentina. Can the anti-hCG 
vaccine prevent these abnormalities? Obesity and Metabolic Syndrome 
of Type II Diabetes are increasing problems worldwide. 
Development of a Vaccine against hCG
hCG is composed of 2 subunits : α & β . The alpha subunit is 
common to 3 other pituitary hormones, TSH, LH and FSH; the β 
subunit imparting in each case the hormonal identity. Thus logically the 
immunogen for a vaccine against hCG would be the β subunit and not 
the whole hormone. hCG and its β subunit are however immunologically 
tolerated entities, the mother makes a lot of it and the fetus is exposed 
to it during pregnancy. Thus by themselves, these would not induce any 
antibody response. To make the β subunit immunogenic we linked it to 
a carrier Tetanus Toxoid (TT). TT is an approved safe vaccine, available 
at low price worldwide. It is a recommended vaccine for pregnant 
women. Many die in economically developing countries due to sepsis 
following delivery taking place in asceptic conditions. The logic of 
using a “carrier” was to mobilize T cell help by the “carrier” to the entire 
conjugate, causing the formation of antibodies against both tetanus as 
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Abstract
Reviewed is the work which led to the development of a unique vaccine that prevents pregnancy in sexually 
active women without impairment of ovulation and block of their making normally their sex steroid hormones. Being 
given that hCG is not expressed by non-pregnant females, immunization with the vaccine is devoid of any cross-
reaction with any tissue of the body. It is totally reversible and women regained fertility on decline of antibodies. A 
recombinant vaccine has been developed which is highly immunogenic in mice. It is undergoing extensive toxicology 
under GLP conditions in rodents and a primate species, the marmosets, before resumption of clinical trials.
Ectopic expression of hCG or its subunits takes place in a variety of cancers, particularly at advanced stage 
with adverse survival and poor prognosis. Anti-hCG antibodies exercise therapeutic action against such cancers as 
indicated by in vitro culture and in vivo studies in nude mice.
Transgenic hCG β mice put on weight and manifest insulin resistance. Immunization of these mice with the 
recombinant hCG β-LTB vaccine prevents obesity and insulin resistance.
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well as hCG. Originally a hypothesis, it was proven to be correct. Four 
women who had completed their desired family and had come to the 
clinic to get their Fallopian tubes ligated, agreed to get immunized with 
this test vaccine. The vaccine had by then been evaluated for its full safety 
and lack of undesirable side effects in laboratory animals and subhuman 
primates. The entire February 1976 issue of CONTRACEPTION [3] 
reports these studies. Quite interestingly, women did evoke antibodies, 
not only against tetanus, but also against hCG [4]. Figure 1 recalls the 
findings. A 30 year old woman, who had given birth to 4 children and 
had the fifth pregnancy medically terminated, received 4 intramuscular 
injections of the vaccine hCG β – TT at 2 weeks interval. After the third 
injection, antibodies reactive with hCG were detectable in circulation. 
They kept on increasing over time to reach a maximum around day 100, 
after which gradual decline was noticed. In each of the 4 immunized 
women with this vaccine, antibodies declined to zero level in course of 
time [5]. No noticeable side effects of immunization were noticeable. 
The sera carrying anti-hCG antibodies were tested by 
immunoflourescence for possible reactivity with other human tissues 
: thyroid, pituitary, parathyroid, adrenal, testis & ovaries ; not only by 
a renowned Pathologist at the All India Institute of Medical Sciences 
New Delhi (India) but also at Walter & Eliza Hall Institute of Medical 
Research Melbourne (Australia) and WHO Immunopathology 
Reference Laboratory, Geneva (Switzerland). No cross- reaction was 
observed. The sera were also negative for anti-nuclear, antimicrosomal 
antibodies & rheumatoid factor [6].
An important question to ask was whether the antibody generated 
by the β subunit of hCG recognized the whole hCG, the bioactive 
molecule. The immunized subject KW was injected 5000 i.u. of hCG. 
It caused a decline of anti hCG titres indicating the binding of the 
circulating antibodies with the bioactive hormone (Figure 2). The 
titres started rising after 48 hrs to return eventually to near about the 
original levels. No effect of hCG administration was noticeable on the 
anti tetanus titers, thus indicating that the vaccine was engendering two 
independent group of antibodies against the two constituents of the 
conjugate, hCG β and tetanus toxoid.
The clinical study in India was conducted in only 4 women. 
Confirmation of the immunogenicity, reversibility & safety of the 
hCG β-TT vaccine was carried out by the International Committee on 
Contraception Research (ICCR) of the Population Council New York. 
This clinical study was conducted by eminent clinicians in 15 women in 
Sweden, Finland, Chile & Brazil with approval of their National Regulatory 
Authorities. Fourteen women elicited anti–hCG response with the hCG 
β-TT vaccine. It was reversible in all cases. According to them, “clinical 
surveillance, immunologic, hematologic and biochemical tests indicated 
excellent local and systemic tolerance to the antigen. No significant adverse 
effects on menstrual function, endocrine status, or health were found” [7].
Enhancement of immunogenicity
The prototype vaccine hCG β-TT was competent to overcome the 
immunological tolerance to hCG. The titres of the antibodies induced 
were however not high enough to counteract with certainty the high 
amount of hCG made by women in early pregnancy. The next task then 
was to improve the immunogenicity of the vaccine. The beta subunit 
of the two subunit hormones retains the ability to bind non covalently 
with alpha subunit of not only the species hormone but also with those 
of other mammals. Thus a Hetro-Species Dimer (HSD) was created by 
joining the hCG β to alpha subunit of ovine LH [8]. HSD linked to 
TT generated much higher titres of antibodies than with the previous 
hCG β-TT vaccines, with better neutralization capacity in primates. 
The antibodies were devoid of cross-reactivity with human FSH & 
TSH, but were partially cross-reactive with hLH. It was important to 
determine whether this cross- reaction was detrimental. Interestingly 
it was found by both our lab in India and by Population Council Lab in 
New York that a moderate cross-reaction with hLH, so long as it does 
not block ovulation is additive to the fertility control property of the 
antibodies. Thau et al. [9] observed that the corpus luteum of monkeys 
immunized with β-OLH becomes deficient in progesterone production 
which enhances the anti-fertility action of the antibodies. Women 
immunized with either the hCGβ-TT [7,10,11] or HSD-TT vaccine 
[12,13] continued to ovulate. Thus partial cross-reaction with hLH 
as induced by either hCGβ-TT or by the HSD-TT vaccine in women 
did not block ovulation nor derange menstrual regularity in women of 
reproductive age as tested in Sweden, Finland, Chile, Brazil and India.
Does Anti-hCG vaccine prevent pregnancy?
Having determined the safety and reversibility of the HSD anti-
Figure 1: Kinetics of antibody titres against hCG and tetanus in a woman 
K.W 30 years old with 4 children and 1 termination of pregnancy. Xs at the 
upper abicissa indicate the menstruation days, which remained regular post-
immunization [4].
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Figure 2: Antibodies induced by the hCGβ-TT vaccine bound 5000 IU of 
administered hCG, returning back to previous titres in course of time, No 
change was noticed in anti-tetanus titres indicationg 2 independent set of 
antibodies generated by the vaccine in KW [4].
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hCG Vaccine by Phase I clinical trials [12,13] , the crucial question 
was whether the vaccine can prevent an unwanted pregnancy. With 
due approval of the Ethics and Drugs Regulatory Authorities, we 
carried out Phase II efficacy trials, the first of their kind on a potential 
Birth Control Vaccine anywhere in the world. 148 sexually active 
women of proven fertility with at least two children were enrolled by 
written consent. Many of them were hyper-fertile and were coming 
to the clinics for Medical Termination of Pregnancy (MTP). Primary 
immunization was carried out by 3 intra-muscular injections of the 
HSD-TT (Tetanus Toxoid) or HSD-DT (Diphtheria Toxoid) as carrier. 
The alteration of the carrier in the vaccine was done to avoid very 
high titers of anti-carrier antibodies, which cause carrier- induced 
epitope specific non-responsiveness [14]. Booster immunization was 
done as and when the anti-hCG titers were declining below 50 ng 
hCG bio-neutralization capacity per ml of serum. During primary 
immunization, and till such time as the antibodies had not gone above 
the presumed protective threshold of 50 ng/ml, IUD (Intra Uterine 
Device) was inserted to prevent pregnancy, which was removed after 
the woman developed adequate antibodies. While all women made 
antibodies against hCG, 119 (80%) generated titers above 50 ng/ml. 
Only one pregnancy was recorded over 1224 cycles of observation 
above 50 ng/ml titres. This occurred in a woman, whose antibody titer 
had declined below 50 ng/ml and she was late in taking the booster. 
Twenty six such pregnancies occurred in women: 5 in women at titers 
below 5 ng/ml, 6 in women with titers of 10 ng/ml, 6 at 20 ng/ml and in 
9 with titers between 20-35 ng/ml [15]. Twenty two of these 26 women 
had their pregnancies terminated, but 4 women carried the pregnancy 
to term and delivered normal babies (three boys and one girl). These 
observations indicated that in case a woman conceives at lower than 
35 ng/ml antibody titers, the low antibodies do not interfere in normal 
progression of pregnancy. The vaccine was highly protective above 50 
ng/ml anti-hCG titers. Figure 3 reproduced from the relevant paper 
[15] shows the antibody response in 4 representative women. The solid 
black line gives the period over which she was exposed to pregnancy. 
In each case boosters were given when titers were declining towards 
the presumed protective threshold titers. Eight women completed 30 
cycles without becoming pregnant, nine were protected over 24-29 
cycles, 12 for 18-23 cycles, 15 for 12-17 cycles and 21 for 16-11 cycles. 
The reversibility of the vaccine and regain of fertility is indicated by a 
case represented in Figure 4. A 30 year old subject with two children 
and one termination was protected from becoming pregnant for a year, 
so long as she was taking booster injections as and when the titers were 
tending to decline. She conceived in the cycle when her antibody titers 
were below 5 ng/ml [15]. 
Figure 3: Anti-hCG response to the HSD vaccine in 4 sexually active women of proven fertility. MRG 30yr old and TRW 23yr old had 2 children each; HJN 32yr & 
SVN 29yr old had 2 children each and 1 elective termination of pregnancy. All of them remained protected from becoming pregnant over 26-32 cycles, at top edge 
represent the menstrual events which remained regular, solid lines denote the period over which they were exposed to pregnancy. Booster injections were given to 
keep antibody titres above 50 ng/ml [15].
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Making of a recombinant vaccine against hCG
The merits of immunization against hCG for control of fertility 
without impairment of ovulation and derangement of menstrual 
regularity or bleeding profiles were demonstrated by Phase I & Phase 
II Clinical trials. The eventual large scale production of the vaccine of 
consistent characterstics would require a recombinant vaccine, which 
would (a) ensure that the “carrier” is linked to the hormonal subunit 
at a defined position and (b) be amenable to industrial production. 
This was achieved by a gene construct in which β subunit of heat 
labile enterotoxin of E.coli (LTB) was fused at the C-terminal of hCG β 
(Figure 5). hCG β-LTB was expressed in Pischia pastoris , an expression 
host employed by an industrial company in India to make the Hepatitis 
B vaccine. This vaccine is approved by The Drugs Controller General 
of India for human use. The cost of this vaccine is much lower than the 
Hep B Vaccine made and sold in other countries. 
The recombinant hCG-β-LTB was evaluated for immunogenecity 
in Balb c [16] and four other genetic strains of mice [17]. It was 
adsorbed on alhydrogel and given intra-muscularly. Mycobacterium 
indicus pranii (MIP) a non-pathogenic mycobacteria was employed 
as adjuvant. MIP was originally developed as an immunotherapeutic 
vaccine for multibacillary leprosy [18]. It is approved by The Drugs 
Controller General of India (DCGI) and USFDA. It is licensed to 
Cadilla Pharma and is available for public use. Besides leprosy, MIP is 
being used as adjunct to Multi drugs regimen for treatment of category 
II, (difficult to treat) tuberculosis patients. It is a potent invigorator of 
immune response [17]. MiP is also effective in exercising preventive 
and therapeutic action in development of SP2/ 0 myelomas in mice [19].
Figure 6 shows the antibody response to hCG β-LTB in Balb c 
mice. Antibodies were generated in every mouse (100% positivity) with 
bioefficacy titers well over the protective threshold. A booster given on 
day 127 ensured high titers (upto 6600 ng/ml) in mice over 8 months 
of observation period. 
The recombinant vaccine hCB β-LTB has received approval of the 
National Review Committee on Genetic Manipulation (RCGM). It is 
undergoing Toxicology before going back for clinical trials, under the 
aegis of The Indian Council of Medical Research.
DNA vaccine 
Being given that DNA vaccines are low cost, are thermostable 
and have long shelf life [20], a DNA version of hCG β- LTB was also 
prepared. Codon optimized gene encoding hCGβ-LTB fusion protein 
was PCR amplified, and cloned under the control of cytomegalovirus 
in eukaryotic expression plasmid VR1020 (DJ), which is an approved 
vector for human use by USFDA. The (DJ) version of the vector 1020 
has 45 cpG motifs in the plasmid backbone for better adjuvanticity. 
Although DNA vaccines alone have been shown to be immunogenic 
in chimpanzees [21], and safe in women as per Phase I trial [22], an 
enhanced immune response is obtained by priming with DNA followed 
by protein version of the vaccine [23,24]. Moreover DNA priming 
followed by protein booster induces both antibody and cell mediated 
Figure 4: Regain of fertility on decline of antibodies. STS 30-year with 2 
children and 1 termination remained protected from becoming pregnant over 
12 cycles. She conceived in the cycle when titres were below 20 ng/ml. [15].
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Figure 5: The recombinant hCGβ-LTB vaccine. The carrier β subunit of heat 
labile enterotoxin of E. Coli (LTB) is fused at c-terminal glutamine of hCGβ [16].
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immune responses, which will be particularly useful in therapy of 
cancers expressing hCG. 
Experiments carried out by immunization of mice with only protein 
version of the recombinant hCG β- LTB vaccine, or with DNA priming 
followed by protein version of the vaccine indicate the near about 
doubling of the antibody titers by adopting the latter approach. Hence 
there may be advantage in adopting priming with the DNA vaccine 
followed by protein of hCG-LTB, for immunization with this vaccine.
Ectopic expression of hCG by advanced stage cancers
A number of reports have appeared in the literature on the 
expression of hCG or its subunits by a variety of cancers particularly 
at the advanced stage. Expression of alpha subunit of hCG was 
observed in lung carcinoma tumors [25]. One third of transitional cell 
carcinomas of bladder ectopically produce trophoblastic hormones that 
are specifically correlated with stage and grade of the tumor [26]. β- 
hCG was made ectopically and reported as a poor prognostic marker 
in colorectal cancer [27]. More than 40% of pancreatic exocrine tumors 
produce β hCG [28]. Determination of hCGβ in serum was considered 
as a potential marker in the prognostic evaluation of patients with 
squamous cell carcinoma of the oral cavity and oropharynx [29]. The 
survival of women suffering from cervical carcinoma in whom the 
tumor secreted β hCG was poorer(14%) as compared to those negative 
for β hCG(75%) [30]. Invariably at the stage that ectopic expression of 
hCG/subunits takes place, the cancer is advanced and refractory to the 
currently available drugs. 
We carried out a collaborative study at Sir Gangaram Hospital New 
Delhi on the presence of hCG (as tested immunohistochemically) in 
formalin fixed sections of many tumors. The tumours were also graded. 
Table 1 gives the findings. The frequency of hCG positive tumors 
appears to be higher in high grade advanced tumors.
Being given that a variety of cancers of various origins expresses 
hCG ectopically, it may be relevant to enquire whether hCG plays a 
role in their proliferation. Indeed hCG or its subunits enhance the 
proliferation of tumor cells. Bladder cancer cell line T24, which does 
not produce hCG or its subunits, after treatment with β hCG showed 
a marked increase in proliferation [31]. This action may be result of 
its counter-acting the apoptotic effect of TGFβ-1-induced apoptosis 
[32]. hCG also causes the down-regulation of Fas, Fas ligand, and BAX 
and p53, which are major apoptotic factors [33]. Reduction in β-hCG 
subunit expression in cervical cancer cell lines by silencing RNA led to 
apoptosis of the HeLa cells [34]. Another important action of hCG or its 
subunits is on promotion of angiogenesis by stimulating the migration 
and capillary sprout formation of uterine endothelial cells. High levels 
of hCG and its subunits are associated with high micro vessel density 
in hCG expressing cancers [35]. βhCG down-regulates E-Cadherin and 
thus promotes migration and invasion of cancer cells [36]. A possible 
molecular mechanism by which hCG can promote neoplasm has been 
proposed recently, which suggests that hCG up-regulates the cell cycle 
proteins via the mammalian target of rapamycin complex 1 (mTORC1) 
signalling network [37].
It was relevant to determine whether antibodies directed hCG 
have any role in killing such cells and in preventing their proliferation. 
A study was conducted on A549 lung cancer cells. Their culture in 
vitro in presence of anti-hCG antibodies caused killing of these cells 
(Figure 7). To determine whether the antibodies exercised any effect on 
proliferation of such tumor cells in vivo experiments were carried out 
on Chago human lung tumour cells in nude mice [38]. Figure 8 gives 
the observations showing an inhibition of tumor growth as a function 
of antibody concentration.
Another study was conducted on MOLT-4 cells derived from an 
S.NO. TYPE OF CANCERS TOTAL CASES
EARLY ADVANCED
ALPHA HCG BETA HCG ALPHA HCG BETA HCG
1. INTESTINAL 17 1/4 2/4 2/12 7/12
2. STOMACH 4 - - 2/4 2/4
3. OESOPHAGUS 5 1/1 1/1 2/4 4/4
4. BILE DUCT/GALL BLADDER 9 1/5 2/5 3/4 4/4
5. OVARY 2 - - 0/2 2/2
6. TESTIS 1 - - 1/1 1/1
7. UTERUS/CERVIX 4 0/2 1/2 1/1 1/1
8. BREAST 10 - - 4/10 8/10
9. KIDNEY 5 - - 2/2 2/2
10.  URINARYBLADDER (TCC) 2 - - - -
11. LYMPHOMA (NHL) 1 - - - -
12. PAROTID GLAND 2 - - - -
TOTAL 62 3/12 6/12 17/40 33/40
Table 1:  Expression of α and or β hCG by early and advanced stage tumors.
Figure 7: Dose Dependent Cytotoxicity exercised by a monoclonal anti-hCG-
antibody cPiPP on Lung Cancer cells (A549).
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acute lymphoblastic leukemia patient in relapse. A highly specific 
humanized chimeric recombinant antibody for β hCG (cPiPP) and 
another monoclonal for α hCG (P22376) were employed for studying 
their reactivity with intact as well as permeabilised cells. Their presence 
on membranes and or within cells was investigated. FACS analysis 
indicated the expression of both α and β hCG by the MOLT-4 cells 
(Figure 9). In contrast, no reactivity was seen with a non-specific 
monoclonal antibody Moab730 that was reactive with DU 145 
prostate carcinoma cells. The genuineness of reactivity of the anti-hCG 
antibodies with MOLT-4 cells was further confirmed by competition for 
binding by prior incubation of cells with bioactive hCG [39]. Culture 
of MOLT-4 cells with the anti-hCG antibodies did not however cause 
the killing of the cells. Nevertheless if the same monoclonal antibody 
linked to curcumin was employed, near to 100 % of the cells were killed 
[40] (Figure 10). These observations point to the feasibility of specific 
delivery of drugs to cancer cells by tumor specific antibodies.
The antibodies labeled with 125I could also be used for imaging of 
hCG synthesizing tumors (Figure 11). Their homing primarily to the 
tumor, expressing hCG could also be utilized for specific delivery of 
radiations to such tumors.
Figure 8: Inhibition of tumour induction by anti-α-human chorionic gonadotropin 
(hCG) antibody. Human lung cancer Chago cells (expressing hCGα), 1 x106 in 
0.5 mL of PBS buffer along with different concentrations of anti-hCGα antibody, 
and was transplanted under the dorsal skin of athymic mice (three animals in 
each group). The control group was given transplants of the same number of 
cells and an equivalent amount of normal serum (designated as 0 ng of anti-
hCGα antibody [α-HCG-ab]. Series of panels under A, B, C, D, and E show 
tumour sizes photographed after 2, 4, 6, 8, and 10 weeks, respectively, after 
transplantation of cells with indicated concentrations of antibody [38].
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Figure 9: Reactivity of (a) anti-alpha-hCG (P22376) and (b) anti-beta-hCG 
(cPiPP) antibodies with MOLT-4 cells. FACS analysis was carried out at 
indicated antibody concentrations. In each case, 80-91% cells show binding 
with these antibodies. Histogram in both (a) and (b) shows fluorescence of 
cells without antibody. A non-hCG-reactive monoclonal antibody (MoAb 730) 
demonstrated a lack of recognition (Histogram 6) in (a) [39].
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Figure10: Photomicrograph of MOLT-4 cells after incubation with cPiPP alone 
and cPiPP-curcumin conjugate. Cells incubated in culture medium are used 
as control [40].
Control: MOLT-4 + Medium  20X MOLT-4 + 50µg cPiPP antibody 
alone 40X
Control: MOLT-4 + Medium  40X MOLT-4 + 50µg Curc-cPiPP 
conjugate 40X
Figure 11: Whole body scan of JEG-3 tumor bearing nude mouse injected 
with 131I-anti-hCG monoclonal antibody and 131I-irrelevent monoclonal after 4 
days. Histology and autoradiographs of mouse tumor tissues using 131I labeled 
anti-hCG antibody at 10, 20 and 40X magnification. Control is the non-tumor 
tissue [40].
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Prevention of obesity and insulin resistance 
Susana Rulli has ‘humanised’ mice by making them transgenic 
for hCGβ [41]. It is expressed by human ubiquitine C promoter. The 
transgene is microinjected into the pronuclei of fertilized oocytes of 
FVB/n mice, and implanted into oviducts of pseudo pregnant females. 
The transgenic mice make hCGβ, which combines with the alpha 
subunit of pituitary gonadotropins to generate bioactive hCG. The 
circulating hCG stimulates the production of progesterone which in 
turn promotes the production of large amount of Prolactin, causing 
hypertrophy of pituitary and mammary tumors in many animals. The 
transgenic mice become obese. They also manifest insulin resistance.
Immunization of transgenic hCG β mice with hCGβ-LTB vaccine 
was carried out starting at 3 weeks age with 3 primary injections at 
fortnightly interval followed by a monthly booster. Lo and behold, 
immunization prevented the transgenic mice to become obese, as 
compared to transgenic mice of the same age receiving only saline 
injections (Figure 12). Also the vaccinated mice did not develop insulin 
resistance, which was clearly manifest in non-vaccinated transgenic mice 
(Figure 13). Antibodies generated by the vaccine obviously inactivate 
the circulating hCG, with the result that progesterone and prolactin rise 
is prevented. Hormonal imbalance is apparently one of the causes of 
obesity, which is on an increase worldwide. In USA, approximately 65% 
of the population is overweight [42]. Also type II Diabetes, manifested 
by insulin resistance is a major problem in females accompanied by 
polycystic ovaries and hormonal imbalance. It is too early to speculate 
whether immunization with the anti-hCG vaccine would be of utility 
in such cases. No study has yet been performed on the safety and 
consequences of immunization with the anti-hCG vaccine in obese 
women or those suffering from type II diabetes, although the complete 
lack of any side-effects in women of reproductive age have been well 
established by Phase I/ Phase II clinical trials on the anti-hCG vaccines.
The present observations in transgenic mice are on prevention 
of obesity and related hormonal manifestations (including insulin 
resistance) by active immunization of growing transgenic mice with 
the anti-hCG vaccine. Of great relevance would be to enquire whether 
obesity can or cannot be reversed by active or passive immunization. 
Such studies are in progress. 
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